4578 Federal Register / Vol. 80, No. 18 / Wednesday, January 28, 2015 / Notices 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2015–N–0001] 

Joint Meeting of the Dermatologic and 

Ophthalmic Drugs Advisory Committee 

and Ophthalmic Devices Panel of the 

Medical Devices Advisory Committee; 

Notice of Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

This notice announces a forthcoming 

meeting of a public advisory committee 

of the Food and Drug Administration 

(FDA). The meeting will be open to the 

public. 

Name of Committees: Dermatologic and 

Ophthalmic Drugs Advisory Committee and 

Ophthalmic Devices Panel of the Medical 

Devices Advisory Committee. 

General Function of the Committee: To 

provide advice and recommendations to the 

Agency on FDA’s regulatory issues. 

Date and Time: The meeting will be held 

on February 24, 2015, from 8 a.m. to 5 p.m. 

Location: FDA White Oak Campus, 10903 

New Hampshire Ave., Bldg. 31 Conference 

Center, the Great Room (Rm. 1503), Silver 

Spring, MD 20993–0002. Answers to 

commonly asked questions including 

information regarding special 

accommodations due to a disability, visitor 

parking, and transportation may be accessed 

at: http://www.fda.gov/AdvisoryCommittees/

AboutAdvisoryCommittees/ucm408555.htm. 

Contact Person: Moon Hee V. Choi, Center 

for Drug Evaluation and Research, Food and 

Drug Administration, 10903 New Hampshire 

Ave., Bldg. 31, Rm. 2147, Silver Spring, MD 

20993–0002, 301–796–9001, FAX: 301–847– 

8533, email: DODAC@fda.hhs.gov, or FDA 

Advisory Committee Information Line, 1– 

800–741–8138 (301–443–0572 in the 

Washington, DC area). A notice in the 

Federal Register about last minute 

modifications that impact a previously 

announced advisory committee meeting 

cannot always be published quickly enough 

to provide timely notice. Therefore, you 

should always check the Agency’s Web site 

at http://www.fda.gov/AdvisoryCommittees/

default.htm and scroll down to the 

appropriate advisory committee meeting link, 

or call the advisory committee information 

line to learn about possible modifications 

before coming to the meeting. 

Agenda: The committees will discuss new 

drug application (NDA) 203324, for 

riboflavin ophthalmic solutions with UV–A 

irradiation, submitted by Avedro, Inc. The 

combination products are used in corneal 

collagen cross-linking and proposed to be 

indicated for the treatment of progressive 

keratoconus or corneal ectasia following 

refractive surgery. 

FDA intends to make background material 

available to the public no later than 2 

business days before the meeting. If FDA is 

unable to post the background material on its 

Web site prior to the meeting, the background 

material will be made publicly available at 

the location of the advisory committee 

meeting, and the background material will be 

posted on FDA’s Web site after the meeting. 

Background material is available at http://

www.fda.gov/AdvisoryCommittees/Calendar/

default.htm. Scroll down to the appropriate 

advisory committee meeting link. 

Procedure: Interested persons may present 

data, information, or views, orally or in 

writing, on issues pending before the 

committee. Written submissions may be 

made to the contact person on or before 

February 9, 2015. Oral presentations from the 

public will be scheduled between 

approximately 1 p.m. and 2 p.m. Those 

individuals interested in making formal oral 

presentations should notify the contact 

person and submit a brief statement of the 

general nature of the evidence or arguments 

they wish to present, the names and 

addresses of proposed participants, and an 

indication of the approximate time requested 

to make their presentation on or before 

January 30, 2015. Time allotted for each 

presentation may be limited. If the number of 

registrants requesting to speak is greater than 

can be reasonably accommodated during the 

scheduled open public hearing session, FDA 

may conduct a lottery to determine the 

speakers for the scheduled open public 

hearing session. The contact person will 

notify interested persons regarding their 

request to speak by February 2, 2015. 

Persons attending FDA’s advisory 

committee meetings are advised that the 

Agency is not responsible for providing 

access to electrical outlets. 

FDA welcomes the attendance of the 

public at its advisory committee meetings 

and will make every effort to accommodate 

persons with physical disabilities or special 

needs. If you require special accommodations 

due to a disability, please contact Moon Hee 

V. Choi at least 7 days in advance of the 

meeting. 

FDA is committed to the orderly conduct 

of its advisory committee meetings. Please 

visit our Web site at http://www.fda.gov/

AdvisoryCommittees/

AboutAdvisoryCommittees/ucm111462.htm 

for procedures on public conduct during 

advisory committee meetings. 

Notice of this meeting is given under the 

Federal Advisory Committee Act (5 U.S.C. 

app. 2). 

Dated: January 23, 2015. 

Jill Hartzler Warner, 

Associate Commissioner for Special Medical 

Programs. 

[FR Doc. 2015–01534 Filed 1–27–15; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Neurological 

Disorders and Stroke; Notice of 

Meeting 

Pursuant to section 10(a) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of a meeting of the 

Muscular Dystrophy Coordinating 

Committee (MDCC). 

The meeting will be open to the 

public and accessible by live webcast. 

Name of Committee: Muscular Dystrophy 

Coordinating Committee. 

Type of meeting: Open Meeting. 

Date: March 17, 2015. 

Time: 8:30 a.m. to 4:30 p.m. *Eastern 

Time*—Approximate end time. 

Agenda: The Muscular Dystrophy 

Coordinating Committee (MDCC) is 

mandated by the MD–CARE Act to ‘‘develop 

a plan for conducting and supporting 

research and education on muscular 

dystrophy through the national research 

institutes, and will periodically review and 

revise the plan.’’ The Committee will discuss 

the draft 2015 Action Plan for the Muscular 

Dystrophies at this meeting. Prior to the 

meeting, an agenda will be posted to the 

MDCC meeting registration Web site: 

https://meetings.ninds.nih.gov/meetings/

MDCC/. 

Registration: To register, please go to: 

https://meetings.ninds.nih.gov/meetings/

MDCC/. 

Webcast Live: For those not able to attend 

in person, this meeting will be webcast at: 

http://videocast.nih.gov/. 

Place: Natcher Conference Center (Building 

45), Conference Room D, National Institutes 

of Health, 9000 Rockville Pike, Bethesda, 

Maryland 20892. 

Contact Person: Glen H. Nuckolls, Ph.D., 

Executive Secretary, Muscular Dystrophy 

Coordinating Committee, National Institute 

of Neurological Disorders and Stroke, NIH, 

6001 Executive Boulevard, NSC 2203, 

Bethesda, MD 20892, (301) 496–5739, 

glen.nuckolls@ninds.nih.gov. 

Any member of the public interested in 

presenting oral comments to the committee 

may notify the Contact Person listed on this 

notice at least 10 days in advance of the 

meeting. Interested individuals and 

representatives of organizations may submit 

a letter of intent, a brief description of the 

organization represented, and a short 

description of the oral presentation. Only one 

representative of an organization may be 

allowed to present oral comments and if 

accepted by the committee, presentations 

may be limited to five minutes. Both printed 

and electronic copies are requested for the 

record. In addition, any interested person 

may file written comments with the 

committee by forwarding their statement to 

the Contact Person listed on this notice. The 

statement should include the name, address, 

telephone number and when applicable, the 

mstockstill on DSK4VPTVN1PROD with NOTICES

Federal Register / Vol. 80, No. 18 / Wednesday, January 28, 2015 / Notices 4579 

business or professional affiliation of the 

interested person. 

Attendance is limited to seating space 

available. Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other reasonable 

accommodations, should inform the Contact 

Person listed below in advance of the 

meeting. 

All visitors must go through a security 

check at the NIH main campus to receive a 

visitor’s badge. A government issued photo 

ID is required. Further information can be 

found at the registration Web site: https://

meetings.ninds.nih.gov/meetings/MDCC/. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.853, Clinical Research 

Related to Neurological Disorders; 93.854, 

Biological Basis Research in the 

Neurosciences, National Institutes of Health, 

HHS) 

Dated: January 22, 2015. 

Carolyn Baum, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2015–01484 Filed 1–27–15; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center For Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Cellular 

Aspects of Diabetes and Obesity. 

Date: February 19, 2015. 

Time: 1:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Residence Inn Bethesda, 7335 

Wisconsin Avenue, Bethesda, MD 20814, 

(Telephone Conference Call). 

Contact Person: Reed A Graves, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6166, 

MSC 7892, Bethesda, MD 20892, (301) 402– 

6297, gravesr@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Thrombosis and Vascular. 

Date: February 19, 2015. 

Time: 4:00 p.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Luis Espinoza, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4140, 

MSC 7814, Bethesda, MD 20892, 301–435– 

0952, espinozala@mail.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Clinical and 

Translational Imaging Applications. 

Date: February 20, 2015. 

Time: 10:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892. 

Contact Person: Eileen W Bradley, DSC, 

Chief, SBIB IRG, Center for Scientific Review, 

National Institutes of Health, 6701 Rockledge 

Drive, Room 5100, MSC 7854, Bethesda, MD 

20892, (301) 435–1179, bradleye@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Molecular 

Targets for Cancer Intervention. 

Date: February 23, 2015. 

Time: 7:30 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Embassy Suites at the Chevy Chase 

Pavilion, 4300 Military Road NW., 

Washington, DC 20015. 

Contact Person: Careen K Tang-Toth, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6214, 

MSC 7804, Bethesda, MD 20892, (301) 435– 

3504, tothct@csr.nih.gov. 

Name of Committee: Oncology 2— 

Translational Clinical Integrated Review 

Group; Developmental Therapeutics Study 

Section. 

Date: February 23–24, 2015. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Ritz-Carlton Hotel at Pentagon City, 

1250 South Hayes Street, Arlington, VA 

22202. 

Contact Person: Sharon K Gubanich, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6214, 

MSC 7804, Bethesda, MD 20892, (301) 408– 

9512, gubanics@csr.nih.gov. 

Name of Committee: Biobehavioral and 

Behavioral Processes Integrated Review 

Group; Motor Function, Speech and 

Rehabilitation Study Section. 

Date: February 23–24, 2015. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: El Tropicano Riverwalk Hotel, 110 

Lexington Ave, San Antonio, TX 78205. 

Contact Person: Biao Tian, Ph.D., Scientific 

Review Officer, Center for Scientific Review, 

National Institutes of Health, 6701 Rockledge 

Drive, Room 3166, MSC 7848, Bethesda, MD 

20892, 301–402–4411, tianbi@csr.nih.gov. 

Name of Committee: Oncology 1—Basic 

Translational Integrated Review Group; 

Tumor Microenvironment Study Section. 

Date: February 23–24, 2015. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Ritz-Carlton Hotel, 1700 Tysons 

Boulevard, McLean, VA 22102. 

Contact Person: Angela Y Ng, Ph.D., MBA, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6200, 

MSC 7804, Bethesda, MD 20892, 301–435– 

1715, ngan@mail.nih.gov. 

Name of Committee: Vascular and 

Hematology Integrated Review Group; 

Vascular Cell and Molecular Biology Study 

Section. 

Date: February 23–24, 2015. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Doubletree Guest Suites Santa 

Monica, 1707 Fourth Street, Santa Monica, 

CA 90401. 

Contact Person: Larry Pinkus, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4132, 

MSC 7802, Bethesda, MD 20892, (301) 435– 

1214, pinkusl@csr.nih.gov. 

Name of Committee: Brain Disorders and 

Clinical Neuroscience Integrated Review 

Group; Diseases and Pathophysiology of the 

Visual System Study Section. 

Date: February 23–24, 2015. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: The Westin Long Beach, 333 East 

Ocean Boulevard, Long Beach, CA 90802. 

Contact Person: Nataliya Gordiyenko, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5202, 

MSC 7846, Bethesda, MD 20892, 301–435– 

1265, gordiyenkon@csr.nih.gov. 

Name of Committee: Healthcare Delivery 

and Methodologies Integrated Review Group; 

Health Services Organization and Delivery 

Study Section. 

Date: February 23–24, 2015. 

Time: 8:30 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Embassy Suites at the Chevy Chase 

Pavilion, 4300 Military Road NW., 

Washington, DC 20015. 

Contact Person: Jacinta Bronte-Tinkew, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3164, 

MSC 7770, Bethesda, MD 20892, (301) 806– 

0009, brontetinkewjm@csr.nih.gov. 

Name of Committee: Molecular, Cellular 

and Developmental Neuroscience Integrated 

Review Group; Cellular and Molecular 

Biology of Neurodegeneration Study Section. 

Date: February 23–24, 2015. 

Time: 8:30 a.m. to 4:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

mstockstill on DSK4VPTVN1PROD with NOTICES